selegiline
Trade name: zelapar
Approved
Jun 5, 1989
Selegiline, also known as L-deprenyl, is a substituted phenethylamine, a selective, irreversible inhibitor of Type B monoamine oxidase. Selegiline is available in pill form under many brand names (Eldepryl, Carbex, Atapryl) and is used to reduce symptoms in early-stage Parkinson's disease. Selegiline delays the time point when the L-DOPA (levodopa) treatment becomes necessary from about 11 months to about 18 months after diagnosis, which is beneficial despite not being definitive evidence of neuroprotection. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy. Selegiline is also delivered via a transdermal patch (brand name, Emsam) and in this form, Selegiline is used as a treatment for the major depressive disorder. Selegiline (brand name Anipryl) is also used (at extremely high dosages relative to humans) in veterinary medicine to treat the symptoms of Cushing's disease and cognitive dysfunction (Canine Cognitive Dysfunction) in dogs. Side effects of the pill form include, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, increased involuntary movements, agitation, arrhythmia, slow heart rate, delusions, hypertension, new or increased angina pectoris, and syncope. The main side effects of the patch form for depression included application site reactions, insomnia, diarrhea, and sore throat. — NCATS
Clinical trial activity
29 trials · 32 clinical orgs · 21 marketing orgs
Earliest trial started Sep 1, 1994 (NCT00000188)
Timeline
1980s
- Nov 7, 1984
Orphan Drug Designation
- Jun 5, 1989
Somerset Pharmaceuticals — Earliest FDA Approval
- Jun 5, 1989
Somerset Pharmaceuticals — NDA Organization
- Jun 5, 1989
Quagen Pharma — Marketing Organization
1990s
- Jan 1, 1994
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
- Aug 2, 1996
Chartwell Pharmaceuticals — Marketing Organization
- Aug 2, 1996
G & W Laboratories Inc. — Marketing Organization
- Jan 27, 1997
Cosette — Marketing Organization
- Jan 27, 1997
ACP Nimble — Marketing Organization
- Apr 1, 1997
Allied Pharmaceutical Services — Marketing Organization
- Apr 1, 1997
Siegfried — Marketing Organization
- Apr 1, 1997
I3 Pharms — Marketing Organization
- Jun 6, 1997
Apotex — Marketing Organization
- Nov 26, 1997
Mylan — Marketing Organization
- Nov 26, 1997
Dash Pharms — Marketing Organization
- Apr 30, 1998
Boscogen — Marketing Organization
- Apr 30, 1998
Bayshore Pharms Llc — Marketing Organization
- Apr 30, 1998
Kenton — Marketing Organization
- Nov 30, 1998
DAVA Pharmaceuticals — Marketing Organization
- Nov 30, 1998
Novitium Pharma — Marketing Organization
2000s
- Jan 1, 2001
Earliest Phase 3 Sponsor(trial)
- Sep 15, 2003
Lannett Company, Inc. — Marketing Organization
- Jun 14, 2006
Bausch Health Companies — NDA Secondary Org
2010s
- Apr 2, 2019
Pack Pharmaceuticals — Marketing Organization
- Apr 2, 2019
Rising Pharmaceuticals — Marketing Organization
Indications
Approved for
Studied for
- Amphetamine-Related Disorders · Phase 1
- Bipolar Disorder · Phase 4
- Borderline Personality Disorder · Phase 3
- Cocaine-Related Disorders · Phase 3
- Cognition Disorders · Phase 2
- Depression · Phase 3
- Erectile Dysfunction · Phase 4
- Healthy Volunteers · Phase 4
- HIV Infections · Phase 2
- Major Depressive Disorder · Phase 4
- Marijuana Abuse · Phase 2
- Meniere Disease · Phase 1
- Neurocognitive Disorders · Phase 2
- Parkinson Disease · Phase 4
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Schizophrenia · Early Phase 1
- Tobacco Use Cessation · Phase 2
- Tobacco Use Disorder · Phase 2
Mechanism of action
- Monoamine oxidase BINHIBITOR
MAOB inhibitor
Irreversible inhibitor
Approval history
- approvedPriority reviewJun 5, 1989
Chemistry & pharmacology
SMILES
C#CCN(C)[C@H](C)Cc1ccccc1- Mol. weight
- 187.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL972 ↗
- WikipediaSelegiline ↗
- NCATS6W731X367Q ↗
- ChEMBLCHEMBL1200904 ↗
Also known as
- anipryl
- centrapryl 10
- centrapryl 5
- (-)-deprenil
- (-)-deprenyl
- eldepryl
- eldepryl
- eldepryl
- emsam
- emsam
- ensam
- ensam
- l-deprenalin
- l-deprenalin
- l-deprenyl
- l-deprenyl
- l-deprenyl
- (r)-(-)-deprenyl
- (r)-selegiline
- selegilina
- selegilina
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- selegiline
- (-)-selegiline
- (−)-selegiline
- (−)-selegiline
- selegiline hcl
- selegiline hcl
- selegiline hcl
- selegiline hydrochloride
- selegiline hydrochloride
- selegiline hydrochloride
- selegiline hydrochloride
- selegilinum
- selegilinum
- selegina
- selgene
- stilline 10
- stilline 5
- vivapryl
- vivapryl
- zelapar
- zelapar
- zelapar
- zelapar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05938517 | Phase 1 | Jun 2, 2021 | Ludwig Maximilians University |
| NCT04586543 | Phase 2 | May 18, 2020 | E-Group ICT Software Informatikai Zrt., University of Pecs |
| NCT04870372 | Phase 4 | Mar 1, 2020 | Soochow University |
| NCT04130087 | N/A | Sep 18, 2019 | University of Oxford |
| NCT02225548 | Phase 4 | Sep 1, 2014 | University of South Florida |
| NCT01912391 | Phase 3 | Oct 1, 2012 | Mood and Anxiety Research, Inc |
| NCT01495195 | Phase 2 | Feb 1, 2012 | Midwest Biomedical Research Foundation, National Institute on Drug Abuse (NIDA) |
| NCT00390923 | N/A | Jul 1, 2007 | Canadian Tobacco Control Research Initiative, University of Toronto |
| NCT00531947 | Phase 4 | Jul 1, 2007 | Cognitive Research Corporation, Somerset Pharmaceuticals |
| NCT00439413 | Phase 2 | Jun 1, 2007 | Department of Veteran Affairs, National Institute on Drug Abuse (NIDA) |
| NCT00531596 | Phase 4 | Apr 1, 2007 | Somerset Pharmaceuticals |
| NCT00456976 | Early Phase 1 (Phase 1) | Apr 1, 2007 | University of Tabriz |
| NCT00532116 | Phase 4 | Apr 1, 2007 | Somerset Pharmaceuticals |
| NCT00443872 | Phase 4 | Mar 1, 2007 | Bausch Health Companies, Parkinson's Disease and Movement Disorder Center of Boca Raton, University of Kansas |
| NCT00535262 | Phase 4 | Mar 1, 2007 | Columbia University |
| NCT00640159 | Phase 4 | Jan 1, 2007 | Baylor University |
| NCT01330030 | Phase 2 | Jul 1, 2005 | National Institute on Drug Abuse (NIDA), Stanford University |
| NCT00218517 | Phase 2 | Mar 1, 2005 | National Institute on Drug Abuse (NIDA), Yale University |
| NCT00129311 | Phase 2 | Jul 1, 2004 | National Institute on Drug Abuse (NIDA), Yale University |
| NCT00285766 | Phase 3 | Aug 1, 2002 | Somerset Pharmaceuticals |
Organizations
Research & Development (32)
Marketing (24)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ACP Nimble | For profit | MKTG | Jan 27, 1997 |
| Allied Pharmaceutical Services | For profit | MKTG | Apr 1, 1997 |
| Apotex | For profit | SYN | Dec 4, 1998 |
| Apotex | For profit | MKTG | Jun 6, 1997 |
| Bausch Health Companies | For profit | NDA2 | Jun 14, 2006 |
| Bausch Health Companies | For profit | SYN | Jun 14, 2006 |
| Bayshore Pharms Llc | For profit | MKTG | Apr 30, 1998 |
| Boscogen | For profit | MKTG | Apr 30, 1998 |
| Chartwell Pharmaceuticals | For profit | MKTG | Aug 2, 1996 |
| Cosette | For profit | MKTG | Jan 27, 1997 |
| DAVA Pharmaceuticals | For profit | MKTG | Nov 30, 1998 |
| Dash Pharms | For profit | MKTG | Nov 26, 1997 |
| G & W Laboratories Inc. | For profit | MKTG | Aug 2, 1996 |
| I3 Pharms | For profit | MKTG | Apr 1, 1997 |
| Kenton | For profit | MKTG | Apr 30, 1998 |
| Lannett Company, Inc. | For profit | MKTG | Sep 15, 2003 |
| Mylan | For profit | SYN | Apr 1, 1997 |
| Mylan | For profit | MKTG | Nov 26, 1997 |
| Novitium Pharma | For profit | MKTG | Nov 30, 1998 |
| Pack Pharmaceuticals | For profit | MKTG | Apr 2, 2019 |
| Quagen Pharma | For profit | MKTG | Jun 5, 1989 |
| Rising Pharmaceuticals | For profit | MKTG | Apr 2, 2019 |
| Siegfried | For profit | MKTG | Apr 1, 1997 |
| Somerset Pharmaceuticals | For profit | NDA | Jun 5, 1989 |